Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission
dc.contributor.buuauthor | Ali, Rıdvan | |
dc.contributor.buuauthor | Özkalemkaş, Fahir | |
dc.contributor.buuauthor | Özçelik, Tülay | |
dc.contributor.buuauthor | Özkocaman, Vildan | |
dc.contributor.buuauthor | Ozan, Ülkü | |
dc.contributor.buuauthor | Kimya, Yalçın | |
dc.contributor.buuauthor | Köksal, Nilgün | |
dc.contributor.buuauthor | Gülten, Tuna | |
dc.contributor.buuauthor | Yakut, Tahsin | |
dc.contributor.buuauthor | Tunalı, Ahmet | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAH-1854-2021 | tr_TR |
dc.contributor.researcherid | AAG-8495-2021 | tr_TR |
dc.date.accessioned | 2021-07-06T10:17:39Z | |
dc.date.available | 2021-07-06T10:17:39Z | |
dc.date.issued | 2005-08 | |
dc.description.abstract | Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatimb and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation. (c) 2005 Elsevier Ltd. All rights reserved. | en_US |
dc.identifier.citation | Ali, R. vd. (2005). "Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission", Leukemia Research, 29(8), 971-973. | en_US |
dc.identifier.endpage | 973 | tr_TR |
dc.identifier.issn | 0145-2126 | |
dc.identifier.issue | 8 | tr_TR |
dc.identifier.pubmed | 15978950 | tr_TR |
dc.identifier.scopus | 2-s2.0-20544435207 | tr_TR |
dc.identifier.startpage | 971 | tr_TR |
dc.identifier.uri | https://doi.org/10.1016/j.leukres.2005.01.009 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0145212605000536 | |
dc.identifier.uri | http://hdl.handle.net/11452/21125 | |
dc.identifier.volume | 29 | tr_TR |
dc.identifier.wos | 000230369800015 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Pergamon-Elsevier Science | en_US |
dc.relation.journal | Leukemia Research | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Chronic myelogenous leukemia | en_US |
dc.subject | Pregnancy | en_US |
dc.subject | Imatinib | en_US |
dc.subject | Management | en_US |
dc.subject | Oncology | en_US |
dc.subject | Hematology | en_US |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Hematology | en_US |
dc.title | Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) - Outcome of discontinuation of imatinib therapy after achieving a molecular remission | en_US |
dc.type | Article | |
dc.wos.quartile | Q2 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: